Kai-Lieh Lin

Kai-Lieh Lin

Auto-generated profile, based on publicly available information

Kai-Lieh Lin

Center for Mitochondrial Research and Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2018 in Free Radical Research
Verified
Journal Article
Closed access
KLKai-Lieh Lin
Kai-Lieh Lin
KLKai-Jung Lin
Kai-Jung Lin
PWPei-Wen Wang
Pei-Wen Wang
JCJiin-Haur Chuang
Jiin-Haur Chuang
HLHung-Yu Lin
Hung-Yu Lin
TLTsu-Kung Lin
Tsu-Kung Lin
Mitochondrial dysfunction and oxidative stress are underlying contributors to Parkinson’s disease (PD). The reduction of aberrant proteins and dysfunctional mitochondria through constitutive autophagy is essential for neuronal survival. We investigated the neuroprotective effects of the natural red wine extract, resveratrol, on the Complex I inhibitor, rotenone-induced oxidative stress SH-SY5Y cellular model. With rotenone exposure, cellular reactive oxygen species (ROS), apoptosis and cell death increased at both 6 and 18 h; at the same time, mitochondrial membrane potential (ΔΨm) and the balance of mitochondrial dynamic proteins were disrupted, resulting with fragmented mitochondria. Rotenone was also noted to elevate autophagy initiation but downregulate the autophagy flux. Pretreatment with resveratrol to rotenone exposed cells lowered cellular ROS, apoptosis, and increased survival rates. Resveratrol administration also recovered rotenone induced ΔΨm, mitochondria dynamics alteration, and elongated fragmented mitochondria. Both autophagic induction and autophagic flux were enhanced with resveratrol pre-treatment which is compatible with cellular survival. The mitogen-activated protein kinase (MEK) inhibitor, U0126, abolished the rescuing effect of resveratrol on rotenone treated neurons through the inhibition of autophagy flux. Thus, our work implies that the neuroprotective effect of resveratrol works in part through modulation of mitochondria dynamics and upregulating autophagic flux via the MEK/extracellular signal-regulated kinase (ERK) signalling pathway.

9 June 2026 in Annals of Medicine
Verified
Journal Article
Open access
KLKai-Jung Lin
Kai-Jung Lin
KLKai-Lieh Lin
Kai-Lieh Lin
CLChia-Wei Liou
Chia-Wei Liou
Chia-Liang TsaiChia-Liang Tsai
Chia-Liang Tsai
YCYung-Yee Chang
Yung-Yee Chang
TLTsu-Kung Lin
Tsu-Kung Lin
Characterizing clinical associations before Parkinson’s disease (PD) diagnosis may improve understanding of the diagnostic window in real-world care. Using nationwide claims data from Taiwan, clinical patterns and medication exposures recorded before incident PD were examined, and secondary neurological outcomes and all-cause mortality were evaluated during follow-up. A retrospective, population-based case-control study was conducted using Taiwan’s National Health Insurance Research Database (2000–2016). Incident PD cases were matched 1:4 to controls using a two-stage approach: frequency matching on birth year and sex, followed by propensity score matching for healthcare utilization and selected comorbidities. Associations between prespecified comorbidities, medication exposures, and incident PD were estimated using multivariable logistic regression, while Kaplan–Meier methods and Cox proportional hazards models assessed secondary neurological outcomes and all-cause mortality. A total of 2124 patients with PD and 8496 matched controls were included. Within the one-year pre-diagnostic window, incident PD was significantly associated with head injury (adjusted odds ratio [aOR] 2.16), ischemic stroke (aOR 2.90), hepatitis C virus infection (aOR 1.40), hospitalization for bacterial infection (aOR 1.43), chronic exposure to propranolol (aOR 1.72), and proton pump inhibitors (aOR 1.24), whereas hyperlipidemia showed an inverse association (aOR 0.67). During follow-up, PD patients had higher adjusted hazards for secondary neurological outcomes (adjusted hazard ratio [aHR] 2.24; 95% confidence interval [CI] 1.94–2.58) and all-cause mortality (aHR 1.72; 95% CI 1.57–1.89) than controls. These findings highlight priority variables for understanding the complex clinical landscape preceding a formal PD diagnosis.